Alexandra Mazing

Dr. Alexandra Mazing

First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Sankt-Peterburg, Russia
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Autoimmunity Reviews
Verified
Journal Article
Closed access
AMAram Ashotovich Musaelyan
Aram Ashotovich Musaelyan
SLSergey Lapin
Sergey Lapin
VNVladimir Nazarov
Vladimir Nazarov
OTOlga Tkachenko
Olga Tkachenko
BGBoris Gilburd
Boris Gilburd
YSYehuda Shoenfeld
Yehuda Shoenfeld

2 October 2017 in Neurology Research International
Verified
Journal Article
Open access
PDF file
GMGleb Makshakov
Gleb Makshakov
EMEvgeniy Magonov
Evgeniy Magonov
NTNatalia Totolyan
Natalia Totolyan
VNVladimir Nazarov
Vladimir Nazarov
SLSergey V. Lapin
Sergey V. Lapin
EEEvgeniy Evdoshenko
Evgeniy Evdoshenko
Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE were detected with a 3 Tesla scanner on postcontrast fluid-attenuated inversion-recovery (FLAIR) sequence. Expanded Disability Status Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1 weighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease duration (p=0,0098) and higher EDSS score (p=0,039), but not a higher relapse rate (p=0,091). No association of LMCE with higher frequency of contrast-enhancing lesions on T1-weighted images was detected (p=0,3842). Analysis of covariates, adjusted for age, sex, and disease duration, revealed a significant effect of LMCE on the cortex volume (p=0.043, F=2.529), the total grey matter volume (p=0.043, F=2.54), and total ventricular volume (p=0.039, F=2.605). Conclusions. LMCE was shown to be an independent and significant biomarker of grey matter atrophy and disability in MS.

1 June 2021 in Clinical Immunology
Verified
Journal Article
Closed access
AMAnna Malkova
Anna Malkova
Dmitry KudlayDmitry Kudlay
Dmitry Kudlay
UZUlia Zinchenko
Ulia Zinchenko
NGN. Gavrilova
N. Gavrilova
Igor KudryavtsevIgor Kudryavtsev
Igor Kudryavtsev
YSY. Shoenfeld
Y. Shoenfeld

1 January 2017 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Open access
PDF file
VNV. D. Nazarov
V. D. Nazarov
GMGleb Makshakov
Gleb Makshakov
Alexandra MazingAlexandra Mazing
Alexandra Mazing
ESE. A. Surkova
E. A. Surkova
VKV. S. Krasnov
V. S. Krasnov
ASA. A. Skoromets
A. A. Skoromets
Medical article медицинская статья

11 August 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Dmitry KudlayDmitry Kudlay
Dmitry Kudlay
AMAnna Malkova
Anna Malkova
UZUlia Zinchenko
Ulia Zinchenko
SLSergey V. Lapin
Sergey V. Lapin
Alexandra MazingAlexandra Mazing
Alexandra Mazing
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
There is a need to further characterize the antibody response to vimentin in relation to its possible involvement in pathogenicity of sarcoidosis and other lung disorders. Objectives: We investigated serum samples from patients with sarcoidosis, healthy controls and controls with other non-infectious lung diseases., to evaluate levels and frequency of these antibodies. Materials and methods: A retrospective-prospective comparative study was performed in the years 2015–2019. Sera from 93 patients with sarcoidosis, 55 patients with non-infectious lung diseases and 40 healthy subjects was examined for presence of autoantibodies to mutated citrullinated vimentin (anti-MCV). Patients with elevated anti-MCV levels were tested for antibodies to a cyclic citrullinated peptide (anti-CCP) and citrullinated vimentin (anti-Sa). In all cases ELISA assays was used. The results were considered statistically significant at p-value less than 0.05. Results of the study: The high concentrations of anti-MCV antibodies were more frequent in patients with sarcoidosis (40.9% of the cases, 38/93), compared to the control groups (23.6% and 25.0% of cases, respectively). In sarcoidosis, clinical symptoms similar to the autoimmune pathology were described. A moderate positive correlation between the anti-MCV and anti-Sa antibodies (r = 0.66) was found in 13 patients with sarcoidosis. There was no significant difference between the levels of the anti-MCV and the anti-CCP in patients with non-infectious lung diseases and the healthy control group. Conclusion: Antibodies to citrullinated cyclic peptides are not significant in the pathogenesis of sarcoidosis and other investigated pulmonary diseases (COPD, granulomatosis with polyangiitis, alveolitis) and based on their low concentration, it can be assumed that citrullination and modification of vimentin is not a key factor in the development of an autoimmune response in patients with sarcoidosis.

30 January 2020 in Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
MPMargarita Y. Pervakova
Margarita Y. Pervakova
Alexandra MazingAlexandra Mazing
Alexandra Mazing
SLSergey V. Lapin
Sergey V. Lapin
OTOlga Y. Tkachenko
Olga Y. Tkachenko
ABAnna I. Budkova
Anna I. Budkova
OTOlga N. Titova
Olga N. Titova
Chronic obstructive pulmonary disease (COPD) is multifactorial disease, which is characterized by airflow limitation and can be provoked by genetic factors, including carriage of the PiZ allele of the protease inhibitor (Pi) gene, encoding alpha-1 antitrypsin (A1AT). Both homozygous and heterozygous PiZ allele carriers can develop COPD. It was found recently that normal A1AT regulates cytokine levels, including IL-17, which is involved in COPD progression. The aim of this study was to determine whether homozygous or heterozygous PiZ allele carriage leads to elevated level of IL-17 and other proinflammatory cytokines in COPD patients. Materials and Methods. Serum samples and clinical data were obtained from 44 COPD patients, who included 6 PiZZ, 8 PiMZ, and 30 PiMM A1AT phenotype carriers. Serum concentrations of IL-17, IL-6, IL-8, IFN-γ, and TNF-α were measured by the enzyme-linked immunosorbent assay (ELISA). All A1AT phenotypes were verified by narrow pH range isoelectrofocusing with selective A1AT staining. A turbidimetric method was used for quantitative A1AT measurements. Results. COPD patients with both PiZZ and PiMZ phenotypes demonstrated elevated IL-17 and decreased IFN-γ levels in comparison to patients with the PiMM phenotype of A1AT. Thereafter, the ratio IL-17/IFN-γ in PiZZ and PiMZ groups greatly exceeded the values of the PiMM group. Homozygous PiZ allele carriers also had significantly higher levels of IL-6 and lower levels of IL-8, and IL-6 values correlated negatively with A1AT concentrations. Conclusions. The presence of the PiZ allele in both homozygous and heterozygous states is associated with altered serum cytokine levels, including elevated IL-17, IL-17/IFN-γ ratio, and IL-6 (only PiZZ), but lower IFN-γ and IL-8.